Cosmo Pharmaceuticals NV
Company Profile
Business description
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology, and health tech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. The product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10, and CB-01-33.
Contact
Sir John Rogerson’s Quay
Riverside II
Dublin2
IRLT: +353 18170370
E: investor.relations@cosmopharmaceuticals.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
322
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 7,853.70 | 60.20 | -0.76% |
CAC 40 | 7,104.80 | 21.22 | -0.30% |
DAX 40 | 20,374.10 | 188.63 | -0.92% |
Dow JONES (US) | 40,212.71 | 619.05 | 1.56% |
FTSE 100 | 7,964.18 | 50.93 | 0.64% |
HKSE | 20,914.69 | 232.91 | 1.13% |
NASDAQ | 16,724.46 | 337.14 | 2.06% |
Nikkei 225 | 33,585.58 | 1,023.42 | -2.96% |
NZX 50 Index | 12,019.13 | 182.30 | -1.49% |
S&P 500 | 5,363.36 | 95.31 | 1.81% |
S&P/ASX 200 | 7,646.50 | 63.10 | -0.82% |
SSE Composite Index | 3,238.23 | 14.59 | 0.45% |